Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Monday, November 25, 2019

Gene Therapy : 1st 2 USA cases went well

Gene Therapy will likely be the ultimate cure for SUB-PAR FMO3 function ('TMAU1').
The 1st 2 cases of CRISPR Gene Therapy in the USA are happening this year.
An update this week said they were going well (after initial therapy).
The 1st 2 cases are for Genetic blood disorders.
It's likely over the years it will be good for all genetic disorders (especially single gene).

Gene Therapy quick unchecked history
pre-2012 : very difficult to do
2012 : CRISPR method makes gene knock in/out very easy and affordable. Seen as a 'T-model Ford' moment.
2019 : Base Editing method shown. Most single-gene disorders will need base editing.
2019 : First 2 cases of use in humans for single-gene disorder.

FMO3 Gene Therapy
It's unknown when FMO3 would be trialed by a health system or private company.
All the 'obvious serious' genetic disorders are ;likely to be at the front of the queue.
They still need to see how the 2 cases get on (but looking good after around 3 months).
They will need to find out delivery methods, and spend millions on research etc.
But an excellent start, and FMO3 should (in most cases) be straightforward base editing (not always).


Link (New Atlas) : Encouraging early results from first human CRISPR gene therapy trials

NIH Directors Blog post
"As groundbreaking as CRISPR/Cas9 has been for editing specific genes, the system has its limitations. The initial version is best suited for making a double-stranded break in DNA, followed by error-prone repair. The outcome is generally to knock out the target. That’s great if eliminating the target is the desired goal. But what if the goal is to fix a mutation by editing it back to the normal sequence?

The new prime editing system, which was described recently by NIH-funded researchers in the journal Nature, is revolutionary because it offers much greater control for making a wide range of precisely targeted edits to the DNA code, which consists of the four “letters” (actually chemical bases) A, C, G, and T "

CRISPR Therapeutics (done the 2 cases) : Press Release Link

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization


Post a Comment